Clinical trials: Hepatocellular Carcinoma Resectable
Hepatocellular Carcinoma Non-resectable
Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis
Hepatocellular carcinoma (HCC) is the most common primary liver cancer, being the third leading cause of cancer-related death worldwide, with approximately 745 000 deaths reported annually.
- Trial name
- IOSPHERE (NCT07122089)
- Testing
- Selective Internal Radiotherapy, Tremelimumab, Durvalumab
- Where
- 6 sites in France
- Volunteers
- 80 people
- Sponsor
- Center Eugene Marquis
Liver Cancer
Vaccine Therapy in Treating Patients With Liver Cancer
RATIONALE: Vaccines made from a person's white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00022334
- Testing
- AFP
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Resectable Hepatocellular Carcinoma
Neoadjuvant Triple Therapy for Resectable HCC
This study is a single-arm, multi-center, prospective phase II trial aimed at evaluating the efficacy and safety of neoadjuvant therapy with transarterial chemoembolization (TACE) combined with lenvatinib and camrelizumab (triple…
- Trial name
- TALENP001 (NCT06569498)
- Where
- 6 sites in China
- Volunteers
- 20 people
- Sponsor
- Fujian Provincial Hospital
Solid Tumor, Adult, Clinical Stage IV Gastric Cancer AJCC v8
Intravital Microscopy in Human Solid Tumors
This study will investigate the tumor-associated vasculature of patients with solid tumors. The investigators will use a technology known as intravital microscopy (IVM) in order to visualize in real-time the vessels associated…
- Conditions
- Solid Tumor, Adult, Clinical Stage IV Gastric Cancer AJCC v8, Malignant Solid Neoplasm, Metastatic Colorectal Carcinoma
- Trial name
- NCT03823144
- Testing
- Diagnostic Microscopy, Fluorescein Sodium Injection
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Mayo Clinic
Hepatic Carcinoma Malignant Primary Non-Resectable
Liquid Biopsy in Hepatocellular Carcinoma
Circulating tumor DNA (ctDNA) carrying tumor-specific sequence alterations has been found in the cell-free fraction of blood. Hepatocellular carcinoma (HCC) specimens are difficult to obtain, and noninvasive methods are required…
- Trial name
- HCCGenePanel (NCT04111029)
- Testing
- Cell Free DNA
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Liver Cancer
Celecoxib and Erlotinib in Treating Patients With Liver Cancer
RATIONALE: Celecoxib and erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. Celecoxib may also stop the growth of liver cancer by blocking blood flow to the tumor.
- Trial name
- NCT00293436
- Testing
- celecoxib, erlotinib hydrochloride, adjuvant therapy
- Where
- United States
- Sponsor
- University of California, San Francisco
Resectable Hepatocellular Carcinoma
Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma.
This is a phase II prospective study to evaluate the safety and efficacy of Tislelizumab monotherapy or combined with lenvatinib as neoadjuvant therapy for resectable hepatocellular carcinoma.
- Trial name
- NCT05807776
- Testing
- Tislelizumab, Tislelizumab, Lenvatinib
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma Non-resectable
Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma
Atezolizumab (anti-programmed death-ligand 1; anti-PD-L1) in conjunction with bevacizumab (anti-vascular endothelial growth factor; anti-VEGF) has become the established standard first-line systemic treatment for unresectable…
- Trial name
- ProtonAB (NCT06133062)
- Testing
- Atezolizumab, Bevacizumab, Proton radiotherapy
- Where
- Taiwan
- Volunteers
- 45 people
- Sponsor
- Chang Gung Memorial Hospital
Hepatocellular Carcinoma Non-resectable
Selective Internal Radiation Therapy and 188Re-SSS Lipiodol Treatment for Liver Cancer (Lip-Re2)
The goal of this monocentric interventional study is to evaluate the efficacy, in terms of objective response rate, of the 188Re-SSS lipiodol SIRT in patients with non-operable HCC.
- Trial name
- Lip-Re2 (NCT05797870)
- Testing
- Selective Internal Radiation Therapy with 188Re-SSS lipiodol
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Center Eugene Marquis
HCC
A Multicenter, Prospective Study of Perioperative Finotonlimab Combined With Bevacizumab in Resectable Hepatocellular Carcinoma Patients With High-Risk Factors for Recurrence
For patients with early- to mid-stage hepatocellular carcinoma (HCC), the five-year postoperative recurrence and metastasis rate remains as high as 70%, significantly impacting patient prognosis.Therefore, perioperative therapy…
- Trial name
- NCT07009470
- Testing
- Finotonlimab (an anti-PD-1 monoclonal antibody) and Anbeizhu (a bevacizumab biosimilar), TACE
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Tongji Hospital
Resectable Hepatocellular Carcinoma With High Risk of Recurrence
Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
This is an open-label, single-arm, multicenter, prospective, phase II clinical study to evaluate the efficacy and safety of TACE combined with Atezolizumab and Bevacizumab as neoadjuvant treatment in Hepatocellular Carcinoma.
- Trial name
- ATTACH (NCT07239245)
- Testing
- Atezolizumab, Bevacizumab, Transarterial chemoembolization (TACE)
- Where
- 4 sites in China
- Volunteers
- 30 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma
MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer
This pilot clinical trial studies magnetic resonance imaging (MRI) with gadoxetate disodium in measuring tumors in patients with liver cancer.
- Conditions
- Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, BCLC Stage 0 Adult Hepatocellular Carcinoma, BCLC Stage A Adult Hepatocellular Carcinoma
- Trial name
- NCT02578602
- Testing
- Gadoxetate Disodium, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Southern California
Hepatocellular Carcinoma Non-resectable
A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and Bevacizumab
Hepatocellular carcinoma (HCC) is the most common liver cancer and a leading cancer death worldwide. Currently, atezolizumab and bevacizumab combination is the standard of care for patients with advanced HCC.
- Trial name
- CPAB (NCT06535737)
- Testing
- Cabozantinib
- Volunteers
- 40 people
- Sponsor
- Chulalongkorn University
HCC
A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk
This study is a single-arm, open-label study. To assess the efficacy and safety of AK112 therapy in patients with resectable hepatocellular carcinoma at high risk of recurrence.
- Trial name
- NCT06930573
- Testing
- AK112
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Hepatocellular Carcinoma
Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma
This study is designed to evaluate the efficacy and safety of sintilimab-bevacizumab doublet combined with FOLFOX-HAIC and TACE as the perioperative adjuvant therapy in surgical resection to hepatocellular carcinoma with…
- Trial name
- NCT07522411
- Testing
- FOLFOX regimen, Immunotherapy, targeted therapy
- Volunteers
- 100 people
- Sponsor
- BinYong Liang
Hepatocellular Carcinoma
Clinical Study Examining the Safety and Efficacy of Doxorubicin Drug Eluting Microspheres Transarterial Embolization in the Setting of Hepatocellular Carcinoma (HCC)
The study is designed to determine whether loading doxorubicin (a type of chemotherapy), when loaded onto a drug eluting microsphere will result in increased destruction of a tumor.
- Trial name
- NCT01116635
- Testing
- doxorubicin, superabsorbent polymer microspheres, embolotherapy
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Liver Cell Carcinoma Non-resectable
Observational Prospective Study on Chemoembolization With Doxorubicin for Unresectable Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the fifth most common type of cancer in men and the seventh in women and is the third most common cause of death from cancer worldwide.
- Trial name
- DEBDOX (NCT01891539)
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- International Group of Endovascular Oncology
Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Tislelizumab Combined With IMRT Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT
Due to the biological characteristics and liver anatomical characteristics of liver cancer, liver cancer cells easily invade the vascular system, especially the portal venous system, forming portal vein tumor thrombus (PVTT) …
- Trial name
- NCT04850157
- Testing
- Tislelizumab, IMRT
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma Non-resectable
Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular Carcinoma
The study investigates the adjuvant SBRT following TACE in early and intermediate stages HCC not amenable for surgical resection.
- Trial name
- ASTrH (NCT04996914)
- Testing
- TACE, SBRT
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- RWTH Aachen University
Localized Non-Resectable Adult Hepatocellular Carcinoma
Stereotactic Body Radiotherapy for Unresectable Hepatocellular Carcinoma
1. Background 1.1. Hepatocellular carcinoma (HCC) HCC is the third most common cause of cancer death globally. It is also the second cause of cancer mortality in Korea, despite the incidence of HCC was fifth.
- Trial name
- SBRT for HCC (NCT01910909)
- Testing
- Stereotactic body radiotherapy
- Where
- South Korea
- Volunteers
- 56 people
- Sponsor
- Samsung Medical Center